S&P 500   4,975.51 (-0.60%)
DOW   38,563.80 (-0.17%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
S&P 500   4,975.51 (-0.60%)
DOW   38,563.80 (-0.17%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
S&P 500   4,975.51 (-0.60%)
DOW   38,563.80 (-0.17%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
S&P 500   4,975.51 (-0.60%)
DOW   38,563.80 (-0.17%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)

Corcept Therapeutics (CORT) Earnings Date, Estimates & Call Transcripts

$22.58
-0.13 (-0.57%)
(As of 02/20/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 1Estimated
Actual EPS
(Feb. 15)
$0.28 Beat By $0.03
Consensus EPS
(Feb. 15)
$0.25
Skip Charts & View Estimated and Actual Earnings Data

CORT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CORT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Corcept Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20244($0.02)$0.31$0.14 
Q2 20244($0.05)$0.36$0.16 
Q3 20244($0.08)$0.38$0.16 
Q4 20244($0.09)$0.46$0.21 
FY 202416($0.24)$1.51$0.66 
Q1 20251$0.17$0.17$0.17 
Q2 20251$0.19$0.19$0.19 
Q3 20251$0.21$0.21$0.21 
Q4 20251$0.28$0.28$0.28 
FY 20254$0.85$0.85 $0.85

CORT Earnings Date and Information

Corcept Therapeutics last released its earnings results on February 15th, 2024. The biotechnology company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.03. The firm had revenue of $135.41 million for the quarter, compared to the consensus estimate of $129.27 million. Its quarterly revenue was up 31.4% compared to the same quarter last year. Corcept Therapeutics has generated $0.95 earnings per share over the last year ($0.95 diluted earnings per share) and currently has a price-to-earnings ratio of 24.0. Earnings for Corcept Therapeutics are expected to grow by 41.67% in the coming year, from $0.72 to $1.02 per share. Corcept Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 1st, 2024 based off prior year's report dates.

Corcept Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/1/2024
Estimated)
------- 
2/15/2024Q4 2023$0.25$0.28+$0.03$0.28$129.27 million$135.41 million    
11/1/2023Q3 2023$0.22$0.28+$0.06$0.28$119.71 million$123.60 million    
8/2/2023Q2 2023$0.15$0.25+$0.10$0.25$109.60 million$117.72 million    
5/3/2023Q1 2023$0.20$0.14($0.06)$0.14$104.91 million$105.70 million    
2/28/2023Q4 2022$0.23$0.14($0.09)$0.14$106.93 million$103.06 million    
11/3/2022Q3 2022$0.23$0.30+$0.07$0.30$107.73 million$101.73 million
8/3/2022Q2 2022$0.25$0.24($0.01)$0.24$101.51 million$103.39 million
5/5/2022Q1 2022$0.23$0.20($0.03)$0.20$103.23 million$93.70 million    
2/15/2022Q4 2021$0.22$0.26+$0.04$0.26$101.17 million$98.82 million    
11/3/2021Q3 2021$0.19$0.24+$0.05$0.24$97.75 million$96.13 million    
7/29/2021Q2 2021$0.14$0.21+$0.07$0.21$85.83 million$91.59 million    
5/6/2021Q1 2021$0.21$0.18($0.03)$0.18$96.99 million$79.44 million  
2/22/2021Q4$0.21$0.20($0.01)$0.20$91.80 million$85.74 million  












Corcept Therapeutics Earnings - Frequently Asked Questions

When is Corcept Therapeutics's earnings date?

Corcept Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 1st, 2024 based off last year's report dates. Learn more on CORT's earnings history.

Did Corcept Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Corcept Therapeutics (NASDAQ:CORT) reported $0.28 earnings per share (EPS) to beat the analysts' consensus estimate of $0.25 by $0.03. Learn more on analysts' earnings estimate vs. CORT's actual earnings.

How can I listen to Corcept Therapeutics's earnings conference call?

The conference call for Corcept Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Corcept Therapeutics's conference call transcript?

The conference call transcript for Corcept Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Corcept Therapeutics generate each year?

Corcept Therapeutics (NASDAQ:CORT) has a recorded annual revenue of $482.38 million.

How much profit does Corcept Therapeutics generate each year?

Corcept Therapeutics (NASDAQ:CORT) has a recorded net income of $106.14 million. CORT has generated $0.95 earnings per share over the last four quarters.

What is Corcept Therapeutics's price-to-earnings ratio?

Corcept Therapeutics (NASDAQ:CORT) has a trailing price-to-earnings ratio of 24.04 and a forward price-to-earnings ratio of 31.72.

What is Corcept Therapeutics's EPS forecast for next year?

Corcept Therapeutics's earnings are expected to grow from $0.72 per share to $1.02 per share in the next year, which is a 41.67% increase.


More Earnings Resources from MarketBeat

This page (NASDAQ:CORT) was last updated on 2/20/2024 by MarketBeat.com Staff